Grifols通过为期十年的等离子体研究获得2100万美元,用于开发早期帕金森氏检测生物标志。 Grifols receives $21M to develop early Parkinson's detection biomarkers through a decade-long plasma study.

Grifols是一家医疗保健公司,已收到Michael J.的一笔2 100万美元的赠款。 Grifols, a healthcare company, has received a $21 million grant from the Michael J. 为帕金森病开发早期检测生物标志的福克斯基金会。 Fox Foundation to develop early detection biomarkers for Parkinson's disease (PD). 该项目名为Chronos-PD,将分析十年来等离子体样本,以确定在出现症状前能够预测PD的生物信号。 The project, called Chronos-PD, will analyze plasma samples over a decade to identify biological signals that could predict PD before symptoms appear. 该倡议由Grifols的附属Alkahest牵头,旨在通过促进早期诊断和更有效的治疗,使PD管理发生革命性变化。 This initiative, led by Grifols' subsidiary Alkahest, aims to revolutionize PD management by facilitating earlier diagnosis and more effective treatments.